DAB2 promotes pulmonary fibrosis and may act as an intermediate between IGF‑1R and PI3K/AKT signaling pathways

Liang,Chun-Lian; Li,Xiu-Li; Quan,Xiao-Juan; Zhang,Lin

doi:10.3892/etm.2023.11882

DAB2 promotes pulmonary fibrosis and may act as an intermediate between IGF‑1R and PI3K/AKT signaling pathways

Authors:
- Chun-Lian Liang
- Xiu-Li Li
- Xiao-Juan Quan
- Lin Zhang
View Affiliations

Affiliations: Department of Geriatrics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China
Published online on: March 10, 2023 https://doi.org/10.3892/etm.2023.11882
Article Number: 183
Copyright: © Liang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Idiopathic pulmonary fibrosis (IPF) is a heterogeneous lung disease associated with high mortality. Disabled‑2 (DAB2), an adapter protein, regulates cell‑fibrinogen adhesion and fibrinogen uptake. DAB2 is differentially expressed in mouse fibrotic lungs induced by bleomycin according to a genome microarray analysis based on Gene Expression Omnibus database. However, the role of DAB2 in IPF has not been revealed. A bleomycin‑induced mouse model of pulmonary fibrosis was constructed in the present study. It found that the expression of DAB2 was upregulated in bleomycin‑induced fibrotic lung tissue with collagen fiber deposition and pulmonary interstitium thickening. Colocalization of DAB2 with α‑smooth muscle actin (SMA) was observed in lung tissue sections. In vitro, human lung fibroblast MRC‑5 cells were treated with TGF‑β1 and the expression of DAB2 was increased. Knockdown of DAB2 suppressed cell proliferation and the expression of α‑SMA, collagen I, collagen IV and fibronectin in TGF‑β1‑treated MRC‑5 cells. The phosphorylation levels of PI3K and AKT were suppressed in DAB2‑knockdown cells. IGF‑1/IGF‑1R has been reported to promote pulmonary fibrosis and activate the PI3K/Akt signaling. In the present study, the activation of IGF‑1/IGF‑1R signaling pathways in bleomycin‑induced fibrotic lung tissues were positively associated with DAB2 expression. The phosphorylation level of IGF‑1R was increased in MRC‑5 cells with TGF‑β1 treatment, and DAB2 expression was decreased by silencing of IGF‑1R. This suggested that DAB2 might be a downstream target of the IGF‑1R pathway and thus induced PI3K/AKT signaling activation and fibrogenesis. The current study demonstrated the importance of DAB2 in pulmonary fibrosis and suggested the potential of IGF‑1R/DAB2/PI3K in the pathogenesis of IPF.

View Figures

View References

1	Richeldi L, Collard HR and Jones MG: Idiopathic pulmonary fibrosis. Lancet. 389:1941–1952. 2017.PubMed/NCBI View Article : Google Scholar
2	Kekevian A, Gershwin ME and Chang C: Diagnosis and classification of idiopathic pulmonary fibrosis. Autoimmun Rev. 13:508–512. 2014.PubMed/NCBI View Article : Google Scholar
3	Raghu G, Chen SY, Hou Q, Yeh WS and Collard HR: Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18-64 years old. Eur Respir J. 48:179–186. 2016.PubMed/NCBI View Article : Google Scholar
4	Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, et al: An Official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 192:e3–19. 2015.PubMed/NCBI View Article : Google Scholar
5	Adamali HI and Maher TM: Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Des Devel Ther. 6:261–272. 2012.PubMed/NCBI View Article : Google Scholar
6	Bonella F, Stowasser S and Wollin L: Idiopathic pulmonary fibrosis: Current treatment options and critical appraisal of nintedanib. Drug Des Devel Ther. 9:6407–6419. 2015.PubMed/NCBI View Article : Google Scholar
7	Shenderov K, Collins SL, Powell JD and Horton MR: Immune dysregulation as a driver of idiopathic pulmonary fibrosis. J Clin Invest. 131(e143226)2021.PubMed/NCBI View Article : Google Scholar
8	Sgalla G, Iovene B, Calvello M, Ori M, Varone F and Richeldi L: Idiopathic pulmonary fibrosis: Pathogenesis and management. Respir Res. 19(32)2018.PubMed/NCBI View Article : Google Scholar
9	American Thoracic Society. Idiopathic pulmonary fibrosis. Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 161:646–664. 2000.PubMed/NCBI View Article : Google Scholar
10	Spagnolo P, Tzouvelekis A and Bonella F: The management of patients with idiopathic pulmonary fibrosis. Front Med (Lausanne). 5(148)2018.PubMed/NCBI View Article : Google Scholar
11	Kelly M, Kolb M, Bonniaud P and Gauldie J: Re-evaluation of fibrogenic cytokines in lung fibrosis. Curr Pharm Des. 9:39–49. 2003.PubMed/NCBI View Article : Google Scholar
12	Hernandez DM, Kang JH, Choudhury M, Andrianifahanana M, Yin X, Limper AH and Leof EB: IPF pathogenesis is dependent upon TGFβ induction of IGF-1. FASEB J. 34:5363–5388. 2020.PubMed/NCBI View Article : Google Scholar
13	Aston C, Jagirdar J, Lee TC, Hur T, Hintz RL and Rom WN: Enhanced insulin-like growth factor molecules in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 151:1597–1603. 1995.PubMed/NCBI View Article : Google Scholar
14	Alzahrani AS: PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside. Semin Cancer Biol. 59:125–132. 2019.PubMed/NCBI View Article : Google Scholar
15	Ma H, Liu S, Li S and Xia Y: Targeting growth factor and cytokine pathways to treat idiopathic pulmonary fibrosis. Front Pharmacol. 13(918771)2022.PubMed/NCBI View Article : Google Scholar
16	Tsai HJ and Tseng CP: The adaptor protein Disabled-2: New insights into platelet biology and integrin signaling. Thromb J. 14 (Suppl 1)(S28)2016.PubMed/NCBI View Article : Google Scholar
17	Cheong SM, Choi H, Hong BS, Gho YS and Han JK: Dab2 is pivotal for endothelial cell migration by mediating VEGF expression in cancer cells. Exp Cell Res. 318:550–557. 2012.PubMed/NCBI View Article : Google Scholar
18	Hocevar BA, Smine A, Xu XX and Howe PH: The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway. EMBO J. 20:2789–2801. 2001.PubMed/NCBI View Article : Google Scholar
19	Mei X, Zhao H, Huang Y, Tang Y, Shi X, Pu W, Jiang S, Ma Y, Zhang Y, Bai L, et al: Involvement of Disabled-2 on skin fibrosis in systemic sclerosis. J Dermatol Sci. 99:44–52. 2020.PubMed/NCBI View Article : Google Scholar
20	Wang BW, Fang WJ and Shyu KG: MicroRNA-145 regulates disabled-2 and Wnt3a expression in cardiomyocytes under hyperglycaemia. Eur J Clin Invest: 48, 2018 doi: 10.1111/eci.12867.
21	Lin CM, Fang WJ, Wang BW, Pan CM, Chua SK, Hou SW and Shyu KG: (-)-Epigallocatechin Gallate Promotes MicroRNA 145 Expression against Myocardial Hypoxic Injury through Dab2/Wnt3a/β-catenin. Am J Chin Med. 48:341–356. 2020.PubMed/NCBI View Article : Google Scholar
22	Ma W, Kang Y, Ning L, Tan J, Wang H and Ying Y: Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway. Exp Ther Med. 14:2853–2862. 2017.PubMed/NCBI View Article : Google Scholar
23	Barratt SL, Creamer A, Hayton C and Chaudhuri N: Idiopathic Pulmonary Fibrosis (IPF): An Overview. J Clin Med. 7(201)2018.PubMed/NCBI View Article : Google Scholar
24	Fu L, Rab A, Tang LP, Rowe SM, Bebok Z and Collawn JF: Dab2 is a key regulator of endocytosis and post-endocytic trafficking of the cystic fibrosis transmembrane conductance regulator. Biochem J. 441:633–643. 2012.PubMed/NCBI View Article : Google Scholar
25	Tseng CP, Ely BD, Li Y, Pong RC and Hsieh JT: Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells. Endocrinology. 139:3542–3553. 1998.PubMed/NCBI View Article : Google Scholar
26	Sheng Z, Sun W, Smith E, Cohen C, Sheng Z and Xu XX: Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells. Oncogene. 19:4847–4854. 2000.PubMed/NCBI View Article : Google Scholar
27	Finkielstein CV and Capelluto DG: Disabled-2: A modular scaffold protein with multifaceted functions in signaling. Bioessays. 38 (Suppl 1):S45–S55. 2016.PubMed/NCBI View Article : Google Scholar
28	Hocevar BA, Mou F, Rennolds JL, Morris SM, Cooper JA and Howe PH: Regulation of the Wnt signaling pathway by disabled-2 (Dab2). EMBO J. 22:3084–3094. 2003.PubMed/NCBI View Article : Google Scholar
29	Dong R, Yu J, Yu F, Yang S, Qian Q and Zha Y: IGF-1/IGF-1R blockade ameliorates diabetic kidney disease through normalizing Snail1 expression in a mouse model. Am J Physiol Endocrinol Metab. 317:E686–E698. 2019.PubMed/NCBI View Article : Google Scholar
30	Pineiro-Hermida S, Lopez IP, Alfaro-Arnedo E, Torrens R, Iñiguez M, Alvarez-Erviti L, Ruíz-Martínez C and Pichel JG: IGF1R deficiency attenuates acute inflammatory response in a bleomycin-induced lung injury mouse model. Sci Rep. 7(4290)2017.PubMed/NCBI View Article : Google Scholar
31	Chung EJ, Kwon S, Reedy JL, White AO, Song JS, Hwang I, Chung JY, Ylaya K, Hewitt SM and Citrin DE: IGF-1 Receptor signaling regulates type II pneumocyte senescence and resulting macrophage polarization in lung fibrosis. Int J Radiat Oncol Biol Phys. 110:526–538. 2021.PubMed/NCBI View Article : Google Scholar
32	Koral K and Erkan E: PKB/Akt partners with Dab2 in albumin endocytosis. Am J Physiol Renal Physiol. 302:F1013–1024. 2012.PubMed/NCBI View Article : Google Scholar
33	Goldbraikh D, Neufeld D, Eid-Mutlak Y, Lasry I, Gilda JE, Parnis A and Cohen S: USP1 deubiquitinates Akt to inhibit PI3K-Akt-FoxO signaling in muscle during prolonged starvation. EMBO Rep. 21(e48791)2020.PubMed/NCBI View Article : Google Scholar